<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830153</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001CKR13T</org_study_id>
    <nct_id>NCT01830153</nct_id>
  </id_info>
  <brief_title>RAD001 in Advanced Sarcoma</brief_title>
  <official_title>A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial intends to test the efficacy and safety of RAD001 in patients with advanced
      sarcoma who failed to conventional chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, phase II trial evaluated the efficacy and safety of everolimus in patients
      with metastatic or recurrent bone and soft tissue sarcoma after failure of anthracycline
      and/or ifosfamide.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 16 weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Determined as the proportion of progression-free (complete response, partial response and stable disease) at 16 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as the time from the initiation of everolimus to disease progression or death, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined from the initiation of everolimus to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as the proportion of complete response and partial response per RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Any adverse events occurred during the treatment with study drug.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Soft Tissue Sarcomas</condition>
  <condition>Bone Sarcomas</condition>
  <arm_group>
    <arm_group_label>RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <arm_group_label>RAD001</arm_group_label>
    <other_name>Everolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed metastatic, unresectable bone or soft tissue
             sarcomas who had past treatment with anthracycline and/or ifosfamide to which the
             disease was primarily refractory or progressed after initial response.

          -  Any of above drugs is allowed to be used as adjuvant treatment.

          -  Unidimensionally measurable disease

          -  3 or less than prior chemotherapies

          -  Age 17 years old or older

          -  ECOG performance status 2 or less, Life expectancy 6 month or less

          -  Adequate bone marrow, liver, kidney, and cardiac function

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating patients

          -  Patients with resectable metastasis

          -  Patients with history of CNS metastasis

          -  Gastrointestinal stromal tumors, chondrosarcoma, neuroblastoma

          -  Hypersensitivity to the active substance, to other rapamycin derivatives, or to any of
             the excipients.

          -  Any preexisting medical condition of sufficient severity to prevent full compliance
             with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Hee Ahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <state>N/A = Not Applicable</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeongnam University College of Medicine</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University</name>
      <address>
        <city>Seoul</city>
        <zip>126-1</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 Jul;11(7):1269-75.</citation>
    <PMID>8315424</PMID>
  </reference>
  <reference>
    <citation>Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson IR. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 2000 May;18(10):2081-6.</citation>
    <PMID>10811673</PMID>
  </reference>
  <reference>
    <citation>Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs. 2005;65(2):167-78. Review.</citation>
    <PMID>15631540</PMID>
  </reference>
  <reference>
    <citation>Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537-45.</citation>
    <PMID>7602342</PMID>
  </reference>
  <reference>
    <citation>Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 Jul;18(14):2676-84.</citation>
    <PMID>10894866</PMID>
  </reference>
  <reference>
    <citation>van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, Van Glabbeke M, Verweij J; EORTC Soft Tissue and Bone Sarcoma Group. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002 Dec;38(18):2397-406.</citation>
    <PMID>12460784</PMID>
  </reference>
  <reference>
    <citation>Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005 Aug 18;353(7):701-11. Review.</citation>
    <PMID>16107623</PMID>
  </reference>
  <reference>
    <citation>Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007 Aug;12(8):1007-18. Review.</citation>
    <PMID>17766661</PMID>
  </reference>
  <reference>
    <citation>Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr√ºnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.</citation>
    <PMID>18653228</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Jin-Hee Ahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Soft tissue sarcomas</keyword>
  <keyword>Bone sarcomas</keyword>
  <keyword>RAD001</keyword>
  <keyword>Refractory to conventional chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

